Aldeyra Therapeutics (ALDX) Acquisitions (2019)

Aldeyra Therapeutics' (ALDX) quarterly Acquisitions came in at -$22626.0 in Q4 2019, down 132.45% on a QoQ basis from $69728.0 in Q3 2019.

Aldeyra Therapeutics (ALDX) Acquisitions (2019) Analysis & Trends

Aldeyra Therapeutics (ALDX) has 1 years of Acquisitions data on file, last reported at -$22626.0 in Q4 2019.

Quarterly Acquisitions changed N/A year-over-year to -$22626.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $609464.0 (changed N/A YoY) and the FY2019 annual result came in at $609464.0, changed N/A from the prior year.
Acquisitions fell to -$22626.0 in Q4 2019, from $69728.0 in the prior quarter.
In the past five years, Acquisitions ranged from a high of $562362.0 in Q1 2019 to a low of -$22626.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Aldeyra Therapeutics	91.08 Mn	91.08 Mn	-	-

Download Data